Cancer Database Query Results

Melanoma, Melanoma Skin Cancer: Click to Expand ⟱
Melanoma is a rare form of skin cancer. It is more likely to invade nearby tissues and spread to other parts of the body than other types of skin cancer.

Scientific Papers found: Click to Expand⟱
6467- 1,8-Cin,    Evaluation of in vitro anticancer activity of 1,8-Cineole-containing n-hexane extract of Callistemon citrinus (Curtis) Skeels plant and its apoptotic potential
- in-vitro, Melanoma, A431 - in-vitro, OS, MG63 - in-vitro, Nor, HaCaT
TumCP↓, selectivity↑, AntiCan↑, TumCD↑, Apoptosis↑, Dose↝, ROS↑,
6465- 1,8-Cin,    Eucalyptol targets PI3K/Akt/mTOR pathway to inhibit skin cancer metastasis
- vitro+vivo, Melanoma, NA
TumMeta↓, TumCMig↓, TumCI↓, Vim↓, Snail↓, Slug↓, Twist↓, E-cadherin↓, EMT↓, MMP2↓, MMP9↓, PI3K↓, Akt↓, mTOR↓,
1340- 3BP,    Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study
- Review, Melanoma, NA
Glycolysis↓, HK2↓, LDH↓, OXPHOS↓, angioG↓, H2O2↑, Synergy↑,
5471- AF,    Anti-Tumoral Treatment with Thioredoxin Reductase 1 Inhibitor Auranofin Fosters Regulatory T Cell and B16F10 Expansion in Mice
- vitro+vivo, Melanoma, B16-F10
TrxR1↓, AntiTum↑, ROS↑, NRF2↑, TumCD↑,
5437- AG,    Modulation of PD-L1 by Astragalus polysaccharide attenuates the induction of melanoma stem cell properties and overcomes immune evasion
- in-vivo, Melanoma, B16-F10
CSCs↓, CD133↓, BMI1↓, PD-L1↓, TumCG↓,
1907- AgNPs,  GoldNP,  Cu,    In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands
- in-vitro, Lung, A549 - in-vitro, BC, MCF7 - in-vitro, Melanoma, A375 - in-vitro, Colon, HCT15 - in-vitro, Cerv, HeLa
TrxR↓, eff↓, eff↓, other∅,
4563- AgNPs,  Rad,    Silver nanoparticles enhance neutron radiation sensitivity in cancer cells: An in vitro study
- in-vitro, BC, MCF7 - in-vitro, Ovarian, SKOV3 - in-vitro, GBM, U87MG - in-vitro, Melanoma, A431
RadioS↑, ROS↑, TumCCA↑, Apoptosis↑, ER Stress↑,
4556- AgNPs,    Biofilm Impeding AgNPs Target Skin Carcinoma by Inducing Mitochondrial Membrane Depolarization Mediated through ROS Production
- in-vitro, Melanoma, A431
MMP↓, ROS↑, *toxicity↓, Bacteria↓,
4412- AgNPs,    Biosynthesis and characterization of silver nanoparticles from Asplenium dalhousiae and their potential biological properties
- in-vitro, CRC, HCT116 - in-vitro, Melanoma, A2780S
Bacteria↓, antiOx↑, AntiCan↑, eff↑,
339- AgNPs,    Cancer cell specific cytotoxic potential of the silver nanoparticles synthesized using the endophytic fungus, Penicillium citrinum CGJ-C2
- in-vitro, BC, MCF7 - in-vitro, Melanoma, A431 - in-vitro, HCC, HepG2
TumCD↑,
309- AgNPs,    Interference of silver, gold, and iron oxide nanoparticles on epidermal growth factor signal transduction in epithelial cells
- in-vitro, Melanoma, A431
ROS↑, Akt↓, p‑ERK↓,
346- AgNPs,  RSQ,    Investigating Silver Nanoparticles and Resiquimod as a Local Melanoma Treatment
- in-vivo, Melanoma, SK-MEL-28 - in-vivo, Melanoma, WM35
ROS↑, Ca+2↝, Casp3↑, Casp8↑, Casp9↑, CD4+↑, CD8+↑, tumCV↓, eff↓, *toxicity↓,
2539- AgNPs,  SDT,    Combined effect of silver nanoparticles and therapeutical ultrasound on ovarian carcinoma cells A2780
- in-vitro, Melanoma, A2780S
tumCV↓, sonoP↑, BioEnh↑,
5349- Akk,  immuno,    Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial
- Case Report, Melanoma, NA
eff↑, OS↑, eff↑,
5350- Akk,  immuno,    Enhancing Immune Response in Immunotherapy-Resistant Melanoma Through Fecal Microbiota Transplantation: A Systematic Review
- in-vitro, Melanoma, NA
eff↑,
2646- AL,    Anti-Cancer Potential of Homemade Fresh Garlic Extract Is Related to Increased Endoplasmic Reticulum Stress
- in-vitro, Pca, DU145 - in-vitro, Melanoma, RPMI-8226
AntiCan↑, eff↓, ChemoSen↑, ER Stress↑, tumCV↓, DNAdam↑, GSH∅, HSP70/HSPA5↓, UPR↑, β-catenin/ZEB1↓, ROS↑, HO-2↑, SIRT1↑, GlucoseCon∅, lactateProd∅, chemoP↑,
290- ALA,  HCA,    A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results
- vitro+vivo, Melanoma, B16-F10
TumCG↓, OS↑,
291- ALA,  HCA,  MET,  DFC,    Metabolic therapies inhibit tumor growth in vivo and in silico
- in-vivo, Melanoma, B16-F10 - in-vivo, Lung, LL/2 (LLC1) - in-vivo, Bladder, MBT-2
TumCG↓,
1024- Api,  CUR,    Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
- vitro+vivo, Melanoma, A375 - in-vitro, Melanoma, A2058 - in-vitro, Melanoma, RPMI-7951
TumCG↓, Apoptosis↑, PD-L1↓, STAT1↓, tumCV↓, T-Cell↑,
206- Api,    Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress
- in-vitro, Lung, H1299 - in-vitro, Lung, H460 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, Melanoma, A375 - in-vitro, Lung, H2030 - in-vitro, CRC, SW480
Glycolysis↓, lactateProd↓, PGK1↓, ALDOA↓, GLUT1↓, ENO1↓, ATP↓, Casp9↑, Casp3↑, cl‑PARP↑, PI3K/Akt↓, HK1↓, HK2↓, ROS↑, Apoptosis↑, eff↓, NADPH↓, PPP↓,
244- Api,    Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma
- in-vivo, Melanoma, B16-F10 - in-vivo, Melanoma, A375 - in-vivo, Melanoma, G361
STAT3↓, MMP2↓, MMP9↓, VEGF↓, Twist↓, E-cadherin↑, N-cadherin↓, EMT↓,
243- Api,    Apigenin Attenuates Melanoma Cell Migration by Inducing Anoikis through Integrin and Focal Adhesion Kinase Inhibition
- in-vitro, Melanoma, A375 - in-vitro, Melanoma, A2058
p‑FAK↓, ERK↓, Casp3↑, PARP↑, ITGA5↓,
242- Api,    Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells
- in-vitro, Melanoma, A375 - in-vitro, Melanoma, C8161
ERK↓, PI3k/Akt/mTOR↓, Casp3↑, PARP↑, p‑mTOR↓, p‑Akt↓,
2322- ART/DHA,    Dihydroartemisinin Regulates Self-Renewal of Human Melanoma-Initiating Cells by Targeting PKM2/LDHARelated Glycolysis
- in-vitro, Melanoma, NA
TumCP↓, PKM2↓, LDHA↓, Glycolysis↓,
1369- Ash,    Withaferin A inhibits cell proliferation of U266B1 and IM-9 human myeloma cells by inducing intrinsic apoptosis
- in-vitro, Melanoma, U266
tumCV↓, Apoptosis↑, BAX↑, Cyt‑c↑, Bcl-2↓, cl‑PARP↑, cl‑Casp3↑, cl‑Casp9↑, ROS↑, eff↓,
5387- AsP,  PacT,    Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy
- in-vivo, Melanoma, B16-F10
Dose↝, TumCG↓, TumCP↓, BioAv↓, BioAv↑, other↑, Apoptosis↑, Bax:Bcl2↑, EPR↑, toxicity↝,
4811- ASTX,    Astaxanthin reduces MMP expressions, suppresses cancer cell migrations, and triggers apoptotic caspases of in vitro and in vivo models in melanoma
- vitro+vivo, Melanoma, A375 - vitro+vivo, Melanoma, A2058
ROS↓, MMPs↓, TumCMig↓, TumMeta↓, TumCCA↑, antiOx↑, MMP1↓, MMP2↓, MMP9↓,
4988- ATV,  Dipy,    Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell Lines
- in-vivo, Melanoma, NA
HMGCR↓, SREBP2↑, SREBP2↓, AntiAg↑,
4985- ATV,  Dipy,    Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell Lines
- in-vivo, Melanoma, SK-MEL-28 - in-vitro, BC, MDA-MB-435
HMG-CoA↓, SREBP2↓, Synergy↑, HMGCR⇅, ChemoSen↑,
1529- Ba,    Studies on the Inhibitory Mechanisms of Baicalein in B16F10 Melanoma Cell Proliferation
- in-vitro, Melanoma, B16-F10
ROS↑, eff↓, tumCV↓, Casp3↑, necrosis↑,
2612- Ba,  MF,    The effect of a static magnetic field and baicalin or baicalein interactions on amelanotic melanoma cell cultures (C32)
- in-vitro, Melanoma, NA
SOD1↑, SOD2↑, GPx1↑, Dose?, eff↝, SOD1↓, SOD2↓, GPx1↓,
2598- Ba,    Baicalein inhibits melanogenesis through activation of the ERK signaling pathway
- in-vitro, Melanoma, B16-F10
other↓, other?, ERK↑,
2291- Ba,  BA,    Baicalein and Baicalin Promote Melanoma Apoptosis and Senescence via Metabolic Inhibition
- in-vitro, Melanoma, SK-MEL-28 - in-vitro, Melanoma, A375
LDHA↓, ENO1↓, PKM2↓, GLUT1↓, GLUT3↓, HK2↓, PFK1↓, GPI↓, TPI↓, GlucoseCon↓, TumCG↓, TumCP↓, mTORC1↓, Hif1a↓, Ki-67↓,
5556- BBM,    Berbamine, a novel nuclear factor κB inhibitor, inhibits growth and induces apoptosis in human myeloma cells
- in-vitro, Melanoma, NA
TumCP↓, ChemoSen↑, TumCCA↑, IKKα↓, p65↓, Bcl-xL↓, BID↓, survivin↓,
1376- BBR,  immuno,    Berberine sensitizes immune checkpoint blockade therapy in melanoma by NQO1 inhibition and ROS activation
- in-vivo, Melanoma, NA
OS↑, ROS↑, NQO1↓, ICD↑,
1382- BBR,    Berberine increases the expression of cytokines and proteins linked to apoptosis in human melanoma cells
- in-vitro, Melanoma, SK-MEL-28
Apoptosis↑, necrosis↑, DNAdam↑, TumCCA↑, ROS↑, Casp3↑, p‑P53↑, ERK↑,
1400- BBR,    Set9, NF-κB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells
- in-vitro, Melanoma, U266
ROS↑, TumCCA↑, Apoptosis↑, miR-21↓, Bcl-2↓, NF-kB↓, Set9↑,
2681- BBR,  PDT,    Berberine-photodynamic induced apoptosis by activating endoplasmic reticulum stress-autophagy pathway involving CHOP in human malignant melanoma cells
- in-vitro, Melanoma, NA
Apoptosis↑, cl‑Casp3↑, LC3s↑, ER Stress↑, ROS↑, CHOP/DDIT3↑,
1102- BBR,    Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells
- in-vitro, Melanoma, B16-BL6
TumCMig↓, TumCI↓, EMT↓, p‑PI3K↓, p‑Akt↓, RARα↓, RARβ↑, RARγ↑, E-cadherin↑, N-cadherin↓,
5587- BetA,  Rad,    Effects of betulinic acid alone and in combination with irradiation in human melanoma cells
- in-vitro, Melanoma, NA
TumCG↓, RadioS↑, Apoptosis↑, selectivity↑,
2717- BetA,    Betulinic Acid Induces ROS-Dependent Apoptosis and S-Phase Arrest by Inhibiting the NF-κB Pathway in Human Multiple Myeloma
- in-vitro, Melanoma, U266 - in-vivo, Melanoma, NA - in-vitro, Melanoma, RPMI-8226
Apoptosis↑, TumCCA↑, MMP↓, ROS↑, eff↓, NF-kB↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP1↑, MDA↑, SOD↓, SOD2↓, GCLM↓, GSTA1↓, FTH1↓, GSTs↓, TumVol↓,
9179- BITC,    Benzyl and phenethyl isothiocyanates as promising epigenetic drug compounds by modulating histone acetylation and methylation marks in malignant melanoma
- in-vitro, Melanoma, NA
H3↝, H4↝,
5679- BML,    Bromelain proteinases modulate the cd44 expression on human molt-4/8 leukemia and sk-mel-28 melanoma-cells in-vitro
- in-vitro, Melanoma, SK-MEL-28
CD44↓,
5677- BML,    Bromelain inhibits nuclear factor kappa-B translocation, driving human epidermoid carcinoma A431 and melanoma A375 cells through G(2)/M arrest to apoptosis
- in-vitro, Melanoma, A431 - in-vitro, Melanoma, A375
TumCP↓, Inflam↓, Akt↓, NF-kB↓, COX2/PTGS2↓, GSH↓, ROS↑, MMP↓, TumCCA↑, Apoptosis↑, ChemoSen↑,
5683- BML,    Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway
- in-vitro, Melanoma, NA
COX2/PTGS2↓, MAPK↓, NF-kB↓, TumMeta↓, P53↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, MAPK↓, ERK↓, Akt↓, TumVol↓,
1423- Bos,    Acetyl-11-keto-β-Boswellic Acid Suppresses Invasion of Pancreatic Cancer Cells Through The Downregulation of CXCR4 Chemokine Receptor Expression
- in-vitro, Melanoma, U266 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, SkBr3 - in-vitro, PC, PANC1
CXCR4↓, TumCI↓, HER2/EBBR2↓, NF-kB↓,
5924- CA,    Carnosic acid impedes cell growth and enhances anticancer effects of carmustine and lomustine in melanoma
- vitro+vivo, Melanoma, B16-F10
TumCG↓, TumCCA↑, P21↑, Synergy↑, AST↓, ALAT↓,
1205- Caff,  immuno,    Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody
- in-vivo, Melanoma, B16-F10
OS↑, CD4+↑, CD8+↑, AntiTum↑, TNF-α↑, IFN-γ↑,
1653- Caff,    Higher Caffeinated Coffee Intake Is Associated with Reduced Malignant Melanoma Risk: A Meta-Analysis Study
- Review, Melanoma, NA
AntiCan↑, eff↓,
8700- CAP,    Cold plasma irradiation inhibits skin cancer via ferroptosis
- vitro+vivo, Melanoma, A431
Ferroptosis↑, tumCV↓, TumCMig↓, TumCI↓, ROS↑, DNAdam↑, ATM↑, P53↑, xCT/SLC7A11↓, GPx4↓,

Showing Research Papers: 1 to 50 of 191
Page 1 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 191

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Catalase↓, 1,   Catalase↑, 2,   GCLM↓, 1,   GPx1↓, 1,   GPx1↑, 1,   GPx4↓, 2,   GSH↓, 8,   GSH↑, 2,   GSH∅, 1,   GSR↑, 1,   GSTs↓, 1,   GSTs↑, 1,   H2O2↑, 2,   HO-1↓, 1,   HO-1↑, 2,   HO-2↑, 1,   Iron↑, 1,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↓, 1,   MDA↑, 3,   NQO1↓, 1,   NRF2↓, 3,   NRF2↑, 3,   p66Shc↑, 1,   ROS?, 1,   ROS↓, 7,   ROS↑, 56,   ROS↝, 1,   mt-ROS↑, 1,   SOD↓, 2,   SOD↑, 1,   SOD1↓, 1,   SOD1↑, 1,   SOD2↓, 3,   SOD2↑, 3,   Thiols↝, 1,   TrxR↓, 3,   TrxR1↓, 1,   xCT/SLC7A11↓, 3,  

Metal & Cofactor Biology(tgid=2) ⓘ

FTH1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 2,   CDC25↑, 1,   HSP60/HSPD1↓, 1,   mitResp↑, 1,   mtDam↑, 6,   OCR↓, 1,   OCR↑, 1,   OXPHOS↓, 2,   OXPHOS↑, 2,   PGC-1α↑, 1,   VDAC1↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↑, 1,   ALAT↓, 1,   ALDOA↓, 1,   AMPK↑, 1,   ATP↓, 6,   ATP↑, 1,   ECAR↓, 1,   ECAR∅, 1,   ENO1↓, 2,   GlucoseCon↓, 3,   GlucoseCon∅, 1,   Glycolysis↓, 8,   GPI↓, 1,   GSK‐3β↝, 1,   HK1↓, 1,   HK2↓, 5,   HMG-CoA↓, 1,   lactateProd↓, 4,   lactateProd∅, 1,   LDHA↓, 2,   NADPH↓, 1,   PDK1 / PDPK1↓, 1,   PFK1↓, 1,   PFKFB4?, 1,   PGK1↓, 1,   PKM2↓, 7,   PPP↓, 1,   Pyruv↓, 1,   RARα↓, 1,   RARβ↑, 1,   RARγ↑, 1,   SIRT1↓, 1,   SIRT1↑, 1,   SIRT2↓, 1,   SREBP2↓, 2,   SREBP2↑, 1,   TCA↓, 1,   TPI↓, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

AIF↑, 2,   Apoptosis↑, 67,   BAD↑, 2,   BAX↓, 1,   BAX↑, 20,   Bax:Bcl2↑, 3,   Bcl-2?, 1,   Bcl-2↓, 27,   Bcl-xL↓, 6,   BID↓, 1,   BIM↑, 1,   Casp↑, 3,   cl‑Casp↑, 1,   Casp1↓, 1,   cl‑Casp12↑, 1,   Casp3↑, 35,   cl‑Casp3↑, 7,   Casp7↑, 3,   cl‑Casp7↑, 1,   Casp8↑, 8,   Casp9↑, 17,   cl‑Casp9↑, 3,   cFLIP↓, 1,   Cyt‑c↑, 9,   DIDO1/DIO-1↑, 1,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 2,   IAP2/BIRC3↓, 1,   ICD↑, 2,   Mcl-1↓, 7,   MDM2↓, 2,   Necroptosis↑, 2,   necrosis↑, 2,   p38↑, 1,   p‑p38↓, 1,   p‑p38↑, 1,   PUMA↑, 2,   RIP3↑, 1,   survivin↓, 11,   TumCD↑, 7,   XIAP↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 17,   Akt↑, 1,   p‑Akt↓, 8,   BRAF↓, 1,   CaMKII ↑, 1,   CREB↓, 2,   CREB↑, 1,   cSrc↓, 1,   EGFR↓, 2,   ERK↓, 7,   ERK↑, 4,   p‑ERK↓, 3,   HER2/EBBR2↓, 1,   IGF-1R↓, 2,   p‑IGF-1R↓, 1,   IKKα↓, 2,   JAK1↓, 2,   JAK2↓, 4,   JNK↑, 1,   MAPK↓, 3,   p‑MAPK↓, 1,   p‑MAPK↑, 1,   p‑MEK↓, 1,   mTOR↓, 6,   p‑mTOR↓, 3,   NIK↓, 1,   PI3K↓, 11,   p‑PI3K↓, 2,   PI3K/Akt↓, 1,   PI3k/Akt/mTOR↓, 1,   PIAS-3↑, 1,   PTEN↑, 4,   PTPN6↑, 1,   SHP1↑, 2,   Sp1/3/4↓, 3,   Src↓, 2,   Src↑, 1,   p‑Src↓, 1,   STAT3↓, 10,   p‑STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF2↓, 2,   ATF4↓, 1,   ChrMod↑, 1,   cMyc↓, 4,   H3↝, 1,   H3K4↓, 1,   H4↝, 1,   miR-21↓, 1,   MITF↓, 1,   other?, 1,   other↓, 2,   other↑, 3,   other↝, 3,   other∅, 1,   Set9↑, 1,   tumCV↓, 25,   tumCV↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 3,   eIF2α↑, 1,   p‑eIF2α↑, 3,   ER Stress↑, 6,   HSP70/HSPA5↓, 1,   HSP70/HSPA5↑, 1,   HSP90↓, 2,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 2,   Beclin-1/ATG6↑, 3,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3A↑, 1,   LC3B-II↑, 2,   LC3s↑, 1,   TumAuto↓, 1,   TumAuto↑, 5,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   DNAdam↑, 9,   DNArepair↓, 1,   MDMX↓, 1,   P53↑, 11,   P53↝, 1,   p‑P53↑, 1,   p53 Wildtype↓, 1,   PARP↑, 3,   cl‑PARP↑, 11,   PARP1↑, 1,   cl‑PARP1↑, 3,   PCNA↓, 2,   PCNA↑, 1,   γH2AX↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 2,   CDK4↓, 4,   cycA1/CCNA1↓, 4,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 12,   Ki-67↓, 5,   P21↓, 1,   P21↑, 7,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 2,   TubPol↓, 1,   TumCCA?, 1,   TumCCA↑, 34,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   ALDH1A1↓, 1,   AXIN1↑, 2,   BMI1↓, 1,   CD133↓, 1,   cFos↓, 1,   CSCs↓, 2,   Diff↑, 1,   EP4/PTGER4↑, 1,   Gli1↓, 1,   HH↓, 1,   HMGCR↓, 1,   HMGCR⇅, 1,   IGF-1↓, 1,   p‑IGF-1↓, 1,   Ki-67↓, 5,   Mel↓, 1,   mTORC1↓, 1,   STAT1↓, 1,   TumCG↓, 40,   TumCP↓, 47,   tyrosinase↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   AP-1↓, 2,   Ca+2↑, 2,   Ca+2↝, 1,   cal2↑, 1,   decorin↑, 1,   E-cadherin↓, 1,   E-cadherin↑, 5,   EMT↓, 6,   p‑FAK↓, 2,   Fibronectin↓, 2,   GLI2↓, 1,   GLI3↑, 1,   ITGA5↓, 1,   MMP1↓, 1,   MMP2↓, 6,   MMP9↓, 8,   MMPs↓, 4,   N-cadherin↓, 5,   PGF↓, 1,   Slug↓, 2,   Snail↓, 2,   TET1↑, 1,   TGF-β↓, 1,   TumCI↓, 16,   TumCMig↓, 17,   TumMeta↓, 14,   TumMeta↑, 1,   Twist↓, 3,   uPA↓, 1,   Vim↓, 3,   Zeb1↓, 1,   β-catenin/ZEB1↓, 3,   cl‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 7,   ECM/TCF↓, 1,   Endoglin↑, 1,   Hif1a↓, 3,   NO↓, 1,   VEGF↓, 7,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   CellMemb↑, 1,   EPR↑, 1,   GLUT1↓, 3,   GLUT3↓, 1,   KCNH2/hERG↓, 1,   MMP↓, 17,   MMP↑, 1,   MPT↓, 1,   MPT↑, 1,   sonoP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD155↓, 1,   CD4+↑, 4,   CD44↓, 2,   CD8+↑, 7,   CLP↑, 1,   COX2/PTGS2↓, 7,   CXCL12↓, 1,   CXCL9↓, 2,   CXCR4↓, 2,   DCells↑, 1,   HMGB1↓, 1,   HMGB1↑, 1,   IFN-γ↓, 3,   IFN-γ↑, 1,   IL1↑, 2,   IL10↑, 2,   IL18↓, 1,   IL1β↓, 2,   IL6↓, 3,   Imm↑, 2,   Inflam↓, 3,   IP-10/CXCL-10↓, 1,   MCP1/CCL2↓, 2,   MIP-1β↓, 1,   NF-kB↓, 23,   NLRP3↓, 2,   p50↓, 1,   p65↓, 2,   PD-L1↓, 2,   PGE2↓, 1,   T-Cell↑, 3,   TCF↓, 1,   TILs↑, 1,   TNF-α↓, 2,   TNF-α↑, 2,  

Cellular Microenvironment(tgid=17) ⓘ

pH↑, 1,   TAMS↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ACTH↓, 1,   GR↓, 1,   SRC3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↓, 1,   BioAv↑, 4,   BioAv↝, 1,   BioEnh↑, 1,   ChemoSen↑, 16,   DDS↑, 1,   Dose?, 1,   Dose↓, 1,   Dose↑, 3,   Dose↝, 21,   Dose∅, 5,   eff↓, 19,   eff↑, 22,   eff↝, 3,   GSTA1↓, 1,   Half-Life↓, 1,   Half-Life↝, 2,   P-gp/ABCB1↓, 1,   P450↓, 1,   RadioS↓, 1,   RadioS↑, 2,   selectivity?, 1,   selectivity↑, 25,   Synergy↑, 13,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   BMD↑, 1,   BRAF↓, 1,   EGFR↓, 2,   HER2/EBBR2↓, 1,   IL6↓, 3,   LDH↓, 2,   PD-L1↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 9,   AntiTum↑, 7,   cardioP↑, 1,   chemoP↑, 2,   chemoPv↑, 6,   CR↑, 2,   MusCon↓, 1,   NP/CIPN↑, 1,   ORR↑, 1,   OS↑, 10,   QoL↑, 1,   QoL∅, 1,   Remission↑, 2,   toxicity↓, 5,   toxicity↝, 3,   TumVol↓, 6,   TumW↓, 2,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 2,   GutMicro↑, 2,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr?, 1,  
Total Targets: 405

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   RNS↓, 1,   ROS?, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

PKM2↓, 1,  

Cell Death(tgid=5) ⓘ

cl‑Casp8↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,  

Migration(tgid=13) ⓘ

Ca+2∅, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   Inflam↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   chemoPv↑, 1,   OS↑, 1,   toxicity↓, 6,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,  
Total Targets: 19

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:39  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page